Inhibition of growth of human small cell and non-small cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH)

International Journal of Oncology

Volumn 9, Issue 6, 1996, Pages 1099-1105

  Pinski, Jacek ^a,b   Schally, Andrew V ^a,b   Jungwirth, Andreas ^a,b   Groot, Kate ^a   Halmos, Gabor ^a,b   Armatis, Patricia ^a   Zarandi, Marta ^a,b   Vadillo Buenfil, Manuel ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

GH RH antagonists; IGF I; IGF II; lung cancer; non SCLC; SCLC

Indexed keywords

GROWTH HORMONE RELEASING FACTOR ANTAGONIST; MZ 4 71; MZ 5 156; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR XENOGRAFT;

EID: 0029807034     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.9.6.1099     Document Type: Article

References (39)

1. Moody TW and Cuttitta F: Growth factor and peptide receptors in small lung cancer. Life Sci 52: 1161-1173, 1993.
2. Minuto F, Del Monte P, Barreca A, Alama A, Cariola G and Giordano G: Evidence for autocrine mitogenic stimulation by somatostatin-C/insulin-like growth factor I on an established human lung cancer cell line. Cancer Res 48: 3716-3719, 1988.
3. Siegfried JM and Owens SE: Response of primary human lung carcinomas to autocrine growth factors produced by a lung carcinoma cell line. Cancer Res 48: 4976-4981, 1988.
4. Favoni RE, De Cupis A, Ravera F, Cantoni C, Pirani P, Ardizzoni A, Noonan D and Biassoni R: Expression and function of the insulin-like growth factor I system in human non-small-cell lung cancer and normal lung cell lines. Int J Cancer 56: 858-866, 1994.
5. Macaulay VM, Teale JD, Everard MJ, Joshi GP, Smith IE and Millar JL: Somatomedin-C/insulin-like growth factor-I is a mitogen for human small cell lung cancer. Br J Cancer 57: 91-93, 1988.
6. Macaulay VM, Everard MJ, Teale JD, Trott PA, Van Wyk JJ, Smith IE and Millar JL: Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells. Cancer Res 50: 2511-2517, 1990.
7. Reeve JG, Morgan J, Schwander J and Bleehen NM: Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors. Cancer Res 53: 4680-4685, 1993.
8. Reeve JG, Brinkman A, Hughes S, Mitchell J, Schwander J and Bleehen NM: Expression of insulin-like growth factor (IGF) and IGF-binding protein genes in human lung tumor cell lines. J Natl Cancer Inst 84: 628-634, 1992.
9. Underwood LE and van Wyk JJ: Normal and aberrant growth. In: Williams Textbook of Endocrinology. Wilson JD, Foster DW (eds.) Saunders WB, Company, Philadelphia, 8th edition, pp1079-1138, 1992.
10. Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K, O'Byrne K and Cai R-Z: Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice. Br J Cancer 70: 886-892, 1994.
11. Bogden AE, Taylor JE, Moreau JP, Coy DH and Lepage DJ: Response of human lung tumour xenografts to treatment with a somatostatin analogue (Somatuline). Cancer Res 50: 4360-4365, 1990.
12. Taylor JE, Bogden AE, Moreau JP and Coy DH: In vitro and in vivo inhibition of human small cell lung carcinoma (NCI-H69) growth by a somatostatin analogue. Biochem Biophys Res Comm 153: 81-86, 1988.
13. Pollak MN, Polychronakos C and Guyda H: Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasm potentially dependent on IGF-I. Anticancer Res 9: 889-891, 1989.
14. Schally AV: Oncological applications of somatostatin analogs. Cancer Res 48: 6977-6985, 1988.
15. Zarandi M, Horvath JE, Halmos G, Pinski J, Nagy A, Groot K and Schally AV: Synthesis and biological activities of highly potent antagonist of growth hormone-releasing hormone. Proc Natl Acad Sci USA 91: 12298-12302, 1994.
16. Zarandi M, Kovacs M, Horvath JE, Toth K, Halmos G, Groot K and Schally AV: Synthesis and in vitro biological activities of novel highly potent antagonists of growth hormone-releasing hormone. Peptides (In press).
17. Pinski J, Schally AV, Groot K, Halmos G, Szepeshazi K, Zarandi M and Armatis P: Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone (GH-RH). J Natl Cancer Inst 87: 1787-1794, 1995.
18. Redding TW and Schally AV: Inhibition of growth of transplantable rat chondrosarcoma by analogs of hypothalamic hormones. Proc Natl Acad Sci USA 80: 1078-1082, 1983.
19. D'Ercole AJ, Stiles AD and Underwood LE: Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci USA 81: 935-939, 1984.
20. Breier BH, Gallaher BW and Gluckman PD: Radioimmunoassay for insulin-like growth factor-I: solutions to some potential problems and pitfalls. J Endocrinol 128: 347-357, 1991.
21. Daughaday WH, Mariz IK and Blethen SL: Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: A comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol extracted serum. J Clin Endocrinol Metab 51: 781-788, 1980.
22. Tanaka H, Asami O, Hayano T, Sasaki I, Yoshitake Y and Nishikawa K: Identification of a family of insulin-like growth factor II secreted by cultured rat epithelial-like cell line 18, 54-SF: Application of a monoclonal antibody. Endocrinology 124: 870-877, 1989.
23. Srkalovic G, Szende B, Redding TW, Groot K and Schally AV: Receptors for D-Trp-6-luteinizing hormone-releasing hormone, somatostatin and insulin-like growth factor I in MXT mouse mammary carcinoma. Proc Soc Exp Biol Med 192: 209-218, 1989.
24. Munson PJ and Rodbard D: Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107: 220-239, 1980.
25. Carney DN, Bunn Jr PA, Gazdar AF, Pagan JA and Minna JD: Selective growth in serum-free hormone-supplemented medium of tumor cells obtained by biopsy from patients with small cell carcinoma of the lung. Proc Natl Acad Sci USA 78: 3185-3189, 1981.
26. Plumb JA, Milroy R and Kaye SB: Effects of the pH dependence of 3-(4,5-Dimethylthiazol-2yl)-2, 5-diphenyltetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res 49: 4435-4440, 1989.
27. Steel RGD and Torrie J: Principles, and Procedures of Statistics. McGraw Hill, New York, p114, 1976.
28. Lee PDK, Baker BK, Liu F, Kwan EYW and Hintz RL: A homologous radioimmunoassay for rat insulin-like growth factor-I (IGF-I). Implications for studies of human IGF-I physiology. J Clin Endocrinol Metab 81: 2002-2005, 1996.
29. Crawford BA, Martin JI, Howe CJ, Handelsman DJ and Baxter RC: Comparison of extraction methods for insulin-like growth factor-I in rat serum. J Endocrinol 134: 169-176, 1992.
30. Corpas E, Harman SM, Pineyro MA, Roberson R and Blackman MR: Growth hormone (GH)-releasing hprmone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab 75: 530-535, 1992.
31. Vermeulen A: Nyctohumoral growth hormone prolifes in young and aged men: correlations with somatomedin-C levels. J Clin Endocrinol Metab 64: 884-888, 1987.
32. Ho KY, Evans WS, Blizzard RM, Veldhuis JD, Merriam GR, Samolijik E, Furlanetto R, Rogol AD, Kaiser DL and Thorner MO: Effects of sex and age on 24-hour profile of growth hormone secretion in men: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 64: 51-58, 1987.
33. Fournier B, Ferralli JM, Price PA and Schlaeppi JM: Comparison of the effects of insulin-like growth factor-I and -II on the human osteosarcoma cell line OHS-4. J Endocrinol 136: 173-180, 1993.
34. Ciampani T, Fabbri A, Isidori A and Dufau ML: Growth hormone-releasing hormone is produced by rat Leydig cell in culture and acts as a positive regulator of Leydig cell function. Endocrinology 131: 2785-2792, 1992.
35. Christophe J, Svoboda M, Dehaye JP, Winand J, Vandermeers-Pire MC, Vandermeers A, Cauvin A, Gouerlet P and Robberecht P: The VIP/PHI/secretin/helospectin/GRF family; structure-function relationship of the natural peptides, their precursor and synthetic analogues as tested in vitro on receptors and adenylate cyclase in a panel of tissue membranes. In: Peptide hormones as Prohormones: Processing, Biological Activity, Pharmacology. Martinez J (Ed.) Halsted Press, New York, pp211-242, 1989.
36. Robberecht P, Waelbroeck M, Coy D, DeNeef P, Camus JC and Christophe J: Comparative structural requirements of thirty GRF analogs for interaction with GRF- and VIP receptors and coupling to adenylate cyclase in rat adenopituitary, liver and pancreas. Peptides (Suppl. 1) 7: 53-59, 1986.
37. Laburthe M and Couvineau A: Molecular analysis of vasoactive intestinal peptide receptors. A comparison with receptors for VIP-related peptides. Ann NY Acad Sci 527: 296-313, 1988.
38. Qin Y, Schally AV and Willems G: Somatostatin analogue RC-160 Inhibits the growth of transplanted colon cancer in rats. Int J Cancer 47: 765-770, 1991.
39. Pollak M, Sem AW, Richard M, Tetenes E and Bell R: Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J Natl Cancer Inst 84: 966-971, 1992.